National Bank of Greece completes first tranche of share buyback program

Stratos Molyviatis General Manager - Chief Operations Officer Member of the Executive Committee National Bank of Greece SA
Stratos Molyviatis General Manager - Chief Operations Officer Member of the Executive Committee - National Bank of Greece SA
0Comments

National Bank of Greece S.A. has announced the completion of a share buyback program, which was initiated following resolutions passed at the Annual General Meeting on May 30, 2025. The bank disclosed that from June 4 to June 13, 2025, it acquired a total of 570,422 common shares traded on the Athens Stock Exchange. The shares were purchased at a weighted average price of €10.3844 per share, amounting to a total expenditure of €5,923,470.98.

The bank intends to cancel these acquired shares in line with Law 4548/2018’s provisions regarding the timeframe for cancellation. During this period, specific transactions included purchasing varying numbers of shares each day at different prices:

– On June 4: 200,422 shares at €10.2535 each
– On June 5: 200,000 shares at €10.3513 each
– On June 6: 50,000 shares at €10.4818 each
– On June 10: 10,000 shares at €10.6561 each
– On June 11: 10,000 shares at €10.8161 each
– On June 12: 10,000 shares at €10.7739 each
– On June 13: 90,000 shares at €10.5737 each

After these transactions were completed, the National Bank of Greece holds directly a total of approximately 3.55 million own shares representing about 0.39% of its share capital.

This announcement complies with EU Regulation No (EU) Regulation No (EU) Regulation No (EU) Regulation No (EU) Regulation No (EU) Regulation No (EU) Regulation No (EU) Regulation No (EU).596/2014 and other relevant regulations governing stock market activities in the European Union.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.